MDXG - MiMedx up 15% as net loss narrows in Q3 and beats Street expectations

Shares of wound care company MiMedx Group (MDXG +14.5%) are up in trading today after reporting Q3 2021 EPS and revenue that beat Street expectations. MiMedx's net loss in the quarter narrowed ~88% to ~2.3M. R&D expenses increased 29% to $4.4M due to an increase in headcount in clinical research. SG&A expenses decreased ~4% to $46.3M. MiMedx ended the quarter with $90.6M in cash. For fiscal 2021, the company expects adjusted net sales of $245M to $255M. for FY 20, adjusted net sales were $240.5M. The company will hold an investor day on Dec. 7. Read about a late-stage trial setback MiMedx had in September for its amniotic tissue technology

For further details see:

MiMedx up 15% as net loss narrows in Q3 and beats Street expectations